Biocryst Pharmaceuticals INC (BCRX) — SEC Filings

Q: What are the key financial highlights for Biocryst Pharmaceuticals INC?

Key financial highlights for Biocryst Pharmaceuticals INC are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Biocryst Pharmaceuticals INC?

Key executives at Biocryst Pharmaceuticals INC are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Biocryst Pharmaceuticals INC stock?

Risk factors for Biocryst Pharmaceuticals INC (BCRX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Biocryst Pharmaceuticals INC?

Forward-looking statements and predictions from Biocryst Pharmaceuticals INC are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Biocryst Pharmaceuticals INC. Recent DEFA14A filing on Apr 23, 2026. AI-decoded analysis of earnings, risk factors, and insider trad

View Biocryst Pharmaceuticals INC on SEC EDGAR

Overview

Biocryst Pharmaceuticals INC (BCRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 23, 2026: BioCryst Pharmaceuticals Inc. filed a Definitive Additional Materials (DEFA14A) on April 23, 2026. This filing contains additional soliciting materials related to their business. The company's mailing and business address is 4505 Emperor Boulevard, Suite 200, Durham, NC 27703.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bullish, 48 neutral. The dominant filing sentiment for Biocryst Pharmaceuticals INC is neutral.

Filing Type Overview

Biocryst Pharmaceuticals INC (BCRX) has filed 3 DEFA14A, 32 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

BioCryst Pharmaceuticals Files Additional Proxy Materials — DEFA14A · Apr 23, 2026 Risk: low
BioCryst Pharmaceuticals Inc. filed a Definitive Additional Materials (DEFA14A) on April 23, 2026. This filing contains additional soliciting materials related
BioCryst Pharmaceuticals Files 8-K — 8-K · Dec 12, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on December 12, 2025, reporting on other events and financial statements. The filing does not contain specific finan
8-K Filing — 8-K · Dec 11, 2025
BioCryst Pharmaceuticals Files 8-K — 8-K · Dec 3, 2025 Risk: low
On December 3, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific mater
BioCryst Swings to Profit on Robust Revenue Growth — 10-Q · Nov 4, 2025 Risk: medium
BioCryst Pharmaceuticals Inc. reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, achieving a net incom
8-K Filing — 8-K · Nov 3, 2025
BioCryst Pharmaceuticals Reports 8-K Filing — 8-K · Oct 14, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. announced on October 14, 2025, several key events including the entry into a material definitive agreement, updates on its result
BioCryst Pharmaceuticals Files 8-K — 8-K · Oct 1, 2025 Risk: medium
On October 1, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and report
BioCryst Pharmaceuticals Reports Leadership Changes — 8-K · Aug 11, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. filed an 8-K on August 11, 2025, reporting on the departure of directors or certain officers, the election of directors, and comp
BioCryst Narrows Q2 Loss by 47% on Strong ORLADEYO Sales — 10-Q · Aug 5, 2025 Risk: medium
BioCryst Pharmaceuticals Inc. reported a significant increase in revenue for the three and six months ended June 30, 2025, primarily driven by sales of ORLADEYO
BioCryst Pharmaceuticals Files 8-K on Financials — 8-K · Aug 4, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on August 4, 2025, reporting on its results of operations and financial condition. The filing also includes informat
BioCryst Pharmaceuticals Announces Board and Executive Changes — 8-K · Jul 31, 2025 Risk: medium
On July 25, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes
BioCryst Pharmaceuticals Adds Directors, Updates Officer Compensation — 8-K · Jul 7, 2025 Risk: low
On July 7, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the election of two new directors, Dr. A
BioCryst Pharmaceuticals Enters Material Definitive Agreement — 8-K · Jun 30, 2025 Risk: medium
On June 27, 2025, BioCryst Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executiv
BioCryst Pharmaceuticals Files 8-K — 8-K · Jun 27, 2025 Risk: low
On June 27, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indi
BioCryst Pharmaceuticals Files 8-K: Other Events — 8-K · Jun 25, 2025 Risk: medium
On June 23, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details
BioCryst Pharmaceuticals Reports Director/Officer Changes & More — 8-K · Jun 16, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting events as of June 11, 2025. The filing covers the departure of directors or certain offi
BioCryst Pharmaceuticals Announces Executive and Director Changes — 8-K · Jun 4, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. announced on May 31, 2025, changes in its executive and director roles. The filing details the departure of certain officers and
BioCryst Pharmaceuticals Files 8-K — 8-K · May 14, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on May 14, 2025, reporting other events and financial statements. The filing does not contain specific financial fig
BioCryst Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
BioCryst Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational updates.
BioCryst Pharmaceuticals Files 8-K — 8-K · May 5, 2025 Risk: low
On May 5, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial st
BioCryst Pharmaceuticals Files 8-K on Leadership and Compensation — 8-K · May 1, 2025 Risk: medium
On April 30, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The f
BioCryst Pharma Executive Compensation Revealed — DEF 14A · Apr 24, 2025 Risk: low
BioCryst Pharmaceuticals Inc. filed its DEF 14A on April 24, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing inc
BioCryst Pharmaceuticals Files Proxy Materials — DEFA14A · Apr 24, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on April 24, 2025. This filing is related to their proxy statement and indicate
BioCryst Pharmaceuticals Announces Board and Executive Changes — 8-K · Apr 10, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. announced on April 6, 2025, changes in its executive team. The company elected two new directors, Dr. Robert J. Radcliff and Ms.
BioCryst Pharmaceuticals Files 8-K — 8-K · Mar 11, 2025 Risk: medium
On March 10, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a significant development not cov
BioCryst Pharmaceuticals Announces Board and Compensation Changes — 8-K · Mar 4, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. announced on February 28, 2025, changes in its board of directors and executive compensation arrangements. The filing details the
BioCryst Pharmaceuticals Files 2024 Annual Report — 10-K · Feb 25, 2025 Risk: medium
BioCryst Pharmaceuticals Inc. filed its 2024 10-K on February 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Dur
BioCryst Pharmaceuticals Files 8-K on Financials — 8-K · Feb 24, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on February 24, 2025, reporting on its results of operations and financial condition. The filing also included discl
BioCryst Pharmaceuticals Files 8-K Report — 8-K · Jan 13, 2025 Risk: low
On January 13, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of events and does not disclose specific
BioCryst Pharmaceuticals Files 8-K on Financials — 8-K · Jan 10, 2025 Risk: low
On January 10, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditi
BioCryst Pharmaceuticals Files 8-K — 8-K · Jan 8, 2025 Risk: medium
On January 8, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material informatio
SC 13G/A Filing — SC 13G/A · Nov 7, 2024
BioCryst Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 5, 2024 Risk: medium
BioCryst Pharmaceuticals Inc. reported its third-quarter 2024 results, ending September 30, 2024. The company's financial statements and operational details are
BioCryst Pharmaceuticals Files 8-K — 8-K · Nov 4, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on November 4, 2024, reporting on its results of operations and financial condition. The filing also includes Regula
SC 13G/A Filing — SC 13G/A · Nov 4, 2024
SC 13G/A Filing — SC 13G/A · Oct 17, 2024
BioCryst Pharmaceuticals Files 8-K — 8-K · Oct 2, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on October 2, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does n
BioCryst Pharmaceuticals Files 8-K — 8-K · Sep 30, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on September 30, 2024, reporting on various events. The filing includes financial statements and exhibits, indicatin
SC 13G/A Filing — SC 13G/A · Sep 10, 2024
BioCryst Pharmaceuticals Files 10-Q for Q2 2024 — 10-Q · Aug 6, 2024 Risk: medium
BioCryst Pharmaceuticals Inc. reported its financial results for the period ending June 30, 2024. The company's filing details its financial position and perfor
BioCryst Pharmaceuticals Files 8-K on Financials — 8-K · Aug 5, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on August 5, 2024, reporting on its results of operations and financial condition. The filing also includes Regulati
BioCryst Appoints New Chief Medical Officer — 8-K · Jun 13, 2024 Risk: medium
BioCryst Pharmaceuticals, Inc. announced on June 12, 2024, the appointment of Dr. William P. Sheridan as Chief Medical Officer. Dr. Sheridan previously served a
BioCryst Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
BIOCRYST PHARMACEUTICALS INC (BCRX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. BioCryst Pharmaceuticals Inc. filed a 10-Q report for the perio
BioCryst Pharmaceuticals Files 8-K on Financials — 8-K · May 6, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation
BioCryst Pharmaceuticals Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 25, 2024 Risk: low
BIOCRYST PHARMACEUTICALS INC (BCRX) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The Annual Meeting of Stockholders for BioCryst Pharmaceut
Biocryst Pharmaceuticals Files Proxy Materials — DEFA14A · Apr 25, 2024 Risk: low
Biocryst Pharmaceuticals Inc. filed a Definitive Additional Materials proxy statement on April 25, 2024. This filing is related to the company's proxy solicitat
BioCryst Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
BIOCRYST PHARMACEUTICALS INC (BCRX) filed a Annual Report (10-K) with the SEC on February 27, 2024. BioCryst Pharmaceuticals, Inc. filed its annual report for t
BioCryst Pharmaceuticals Files 8-K on Financial Results — 8-K · Feb 26, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on February 26, 2024, to report its financial condition and results of operations. The filing also included a Regula
SC 13G/A Filing — SC 13G/A · Feb 14, 2024

Risk Profile

Risk Assessment: Of BCRX's 43 recent filings, 0 were flagged as high-risk, 20 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Biocryst Pharmaceuticals INC's most recent 10-Q filing (Nov 4, 2025):

Revenue: $468.282M
Net Income: $18.016M
EPS: $0.09
Cash Position: $84.078M
Total Assets: $446.424M
Total Debt: $834.313M

Key Executives

Dr. Alnawaz
Mr. P. Smith
Dr. Robert J. Radcliff
Ms. Sarah J. Kelly
Dr. Trevor C. Hall
Dr. William P. Sheridan

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like BioCryst operate in a competitive landscape where innovation and successful commercialization of therapies are crucial for growth. The sector is also subject to evolving reimbursement policies and market access challenges.

Top Tags

financials (6) · corporate-governance (5) · 8-k (5) · 10-Q (5) · financial-reporting (5) · sec-filing (4) · filing (4) · executive-compensation (4) · pharmaceuticals (4) · regulation-fd (4)

Key Numbers

Total Revenues: $468.282M — Increased from $319.178 million in 2024, a 46.7% increase, driving profitability.
Net Income: $18.016M — Swing from a net loss of $62.086 million in the prior year period, indicating improved financial health.
Cash and Cash Equivalents: $84.078M — Decreased from $104.713 million at December 31, 2024, reflecting cash utilization despite profitability.
Repayment of Pharmakon term loan principal: $115.847M — Significant cash outflow in financing activities, reducing long-term debt.
Total Stockholders' Deficit: $387.889M — Improved from $(475.934) million, but still represents a negative equity position.
Loss on extinguishment of debt: $6.911M — One-time expense related to debt restructuring, impacting net income.
Basic Net Income Per Common Share: $0.09 — Positive shift from $(0.30) in the prior year, reflecting improved earnings per share.
Net Cash Provided by Operating Activities: $55.409M — Significant improvement from net cash used in operating activities of $(46.807) million in 2024.
Q2 2025 Revenue: $90.5M — Increased by 25.5% from $72.1 million in Q2 2024
Q2 2025 Net Loss: $15.2M — Reduced by 47.4% from $28.9 million in Q2 2024
H1 2025 Revenue: $175.8M — Increased by 26.9% from $138.5 million in H1 2024
H1 2025 Net Loss: $35.1M — Reduced by 42.0% from $60.5 million in H1 2024
Q2 2025 R&D Expenses: $45.3M — Decreased from $50.1 million in Q2 2024
Cash and Cash Equivalents as of June 30, 2025: $200.3M — Decreased from $225.6 million at December 31, 2024
SEC File Number: 000-23186 — Identifies the company's filing history with the SEC.

Related Companies

SHION · GRNC · TAK · CSL · SRPT

Frequently Asked Questions

What are the latest SEC filings for Biocryst Pharmaceuticals INC (BCRX)?

Biocryst Pharmaceuticals INC has 50 recent SEC filings from Feb 2024 to Apr 2026, including 32 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BCRX filings?

Across 50 filings, the sentiment breakdown is: 2 bullish, 48 neutral. The dominant sentiment is neutral.

Where can I find Biocryst Pharmaceuticals INC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Biocryst Pharmaceuticals INC (BCRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Biocryst Pharmaceuticals INC?

Key financial highlights from Biocryst Pharmaceuticals INC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BCRX?

The investment thesis for BCRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Biocryst Pharmaceuticals INC?

Key executives identified across Biocryst Pharmaceuticals INC's filings include Dr. Alnawaz, Mr. P. Smith, Dr. Robert J. Radcliff, Ms. Sarah J. Kelly, Dr. Trevor C. Hall and 1 others.

What are the main risk factors for Biocryst Pharmaceuticals INC stock?

Of BCRX's 43 assessed filings, 0 were flagged high-risk, 20 medium-risk, and 23 low-risk.

What are recent predictions and forward guidance from Biocryst Pharmaceuticals INC?

Forward guidance and predictions for Biocryst Pharmaceuticals INC are extracted from SEC filings as they are enriched.